StockData
Immix Biopharma, Inc. logo

Immix Biopharma, Inc. (IMMX) shareholders

IMMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$7.20−0.28 (-3.74%)

Close on Nov 17, 2026Market cap $515.08MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
78.6%
56M of 72M shares
Institutional holders
109
45 new, 11 sold out
Net institutional buying
34M
In Q2 2026
Insider trades, 12 months
2 buys · 0 sales
Net bought $10.04K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
JANUS HENDERSON GROUP Ltd.9,783,19214.00%13G (passive) amendmentJun 30, 2026
Janus Henderson Group PLC9,090,73213.00%13G (passive) amendmentMay 29, 2026
BlackRock, Inc.4,539,8195.50%13G (passive)Sep 30, 2026
Eventide Asset Management, LLC
Joint filing with Finny Kuruvilla, M.D. Ph. D. (5.60%), Robin C. John (5.60%)
3,891,0195.60%13G (passive)Jun 30, 2026
Saturn V Capital Management LP
Joint filing with Xiaoying Tian (6.97%)
3,693,5856.97%13G (passive)Dec 26, 2025
Millennium Management LLC
Joint filing with Millennium Group Management LLC (5.30%), Israel A. Englander (5.30%)
2,812,2305.30%13G (passive)Mar 13, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of IMMXValueChange% of portfolio
Jupiter Topco LLC9,783,19213.68%$100.82MNew0.04%
Saturn V Capital Management LP4,658,4296.51%$48.03M+964,8446.89%
Eventide Asset Management, LLC3,891,0195.44%$40.12M+1,342,0000.54%
State Street Corp2,996,9354.19%$30.90M+2,805,0250.00%
BlackRock, Inc.2,989,9724.18%$30.83M+2,521,5950.00%
Deep Track Capital, LP2,775,0003.88%$28.61MNew0.42%
Vanguard Capital Management LLC2,507,1223.50%$25.85M+719,1280.00%
Opaleye Management Inc.2,345,0003.28%$24.18MNew2.19%
Millennium Management LLC2,066,4262.89%$21.30M+316,2260.01%
UBS Group AG1,941,8172.71%$20.02M+1,864,9850.00%
Marshall Wace, Llp1,794,9082.51%$18.51M+153,3560.01%
Price T Rowe Associates Inc /Md/1,739,9192.43%$17.94M+1,324,9180.00%
Wellington Management Group Llp1,473,4092.06%$15.19MNew0.00%
Great Point Partners LLC1,277,6421.79%$13.17M+927,6422.49%
Geode Capital Management, LLC1,201,0971.68%$12.39M+737,7130.00%
Velan Capital Investment Management LP1,085,0001.52%$11.19M+345,0006.81%
Logos Global Management LP1,000,0001.40%$10.31M−225,0000.44%
Bleichroeder LP1,000,0001.40%$10.31M–1.84%
Franklin Resources Inc969,1201.35%$9.99M+540.00%
Burkehill Global Management, LP544,1180.76%$5.61M+250,0000.20%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202610956M78.6%45 / 3513 / 1135M1M
Q1 20267727M37.8%24 / 2813 / 128M4M
Q4 20256724M34.1%41 / 176 / 522M0M
Q3 2025313M3.9%12 / 74 / 41M0M
Q2 2025232M3.2%5 / 54 / 40M1M
Q1 2025223M4.1%3 / 49 / 40M0M
Q4 2024233M4.0%5 / 46 / 70M1M
Q3 2024254M5.7%1 / 64 / 60M1M
Q2 2024314M6.2%5 / 512 / 60M1M
Q1 2024355M7.3%14 / 134 / 75M0M
Q4 2023281M1.1%13 / 73 / 10M0M
Q3 2023160M0.6%3 / 80 / 50M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

65 funds held IMMX in Q2 2026, 47% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of IMMXValue% of fundAs of
Eventide Healthcare & Life Sciences Fund3,891,0195.44%$40.12M2.24%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF2,104,0352.94%$21.69M0.20%Jun 30, 2026
Vanguard Total Stock Market Index Fund1,780,4952.49%$18.36M0.00%Jun 30, 2026
T. Rowe Price Health Sciences Fund, Inc.1,326,2561.85%$13.67M0.11%Jun 30, 2026
iShares Russell 2000 ETF1,067,9811.49%$11.01M0.01%Jun 30, 2026
Vanguard Extended Market Index Fund681,4130.95%$7.03M0.01%Jun 30, 2026
Columbia Small Cap Value Discovery Fund483,6300.68%$4.02M0.16%Jul 31, 2026
Fidelity Small Cap Index Fund449,2590.63%$3.74M0.01%Jul 31, 2026
iShares Russell 2000 Growth ETF370,7030.52%$3.82M0.02%Jun 30, 2026
Franklin Biotechnology Discovery Fund357,0340.50%$2.97M0.26%Jul 31, 2026
Fidelity Extended Market Index Fund298,5860.42%$2.69M0.01%May 31, 2026
Timber Point Global Allocations Fund140,0000.20%$1.44M4.51%Jun 30, 2026
iShares Micro-Cap ETF138,1250.19%$1.42M0.09%Jun 30, 2026
Fidelity Total Market Index Fund109,4380.15%$984.94K0.00%May 31, 2026
Schwab Small-Cap Index Fund99,7940.14%$830.29K0.01%Jul 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Ilya M. RachmanCEO and Chairman, Director1,141,6831.60%May 29, 2026
Gabriel S. MorrisCFO, President, Director718,2731.00%May 29, 2026
Jane BuchanDirector28,7050.04%May 29, 2026
Helen C. AdamsDirector181,0040.25%May 29, 2026
Magda MarquetDirector72,3420.10%May 29, 2026
Jason HsuDirector4,815,1636.73%May 29, 2026
Nancy T. ChangDirector925,1301.29%May 29, 2026
Carey NgDirector1,051,4711.47%May 29, 2026
Yekaterina ChudnovskyDirector3,247,3264.54%May 29, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Nancy T. Chang
Director
May 22, 2026Award+6,250––428,190
Magda Marquet
Director
May 22, 2026Award+6,250––52,342
Yekaterina Chudnovsky
Director
May 22, 2026Award+6,250––6,250
Jason Hsu
Director
May 22, 2026Award+6,250––899,250
Helen C. Adams
Director
May 22, 2026Award+6,250––181,004
Jane Buchan
Director
May 22, 2026Award+6,250––28,705
Carey Ng
Director
May 22, 2026Award+6,250––26,250
Ilya M. Rachman
CEO and Chairman, Director
Dec 10, 2025Buy+746$6.67$4.98K1,141,683
Gabriel S. Morris
CFO, Director
Dec 10, 2025Buy+770$6.58$5.07K291,429
Gabriel S. Morris
CFO, Director
Dec 8, 2025Option exercise+156,000$0.80$124.80K426,844
Ilya M. Rachman
CEO and Chairman, Director
Sep 17, 2025Buy+2,500$2.02$5.05K1,140,937
Gabriel S. Morris
CFO, Director
Sep 16, 2025Buy+2,600$1.97$5.12K290,659
Ilya M. Rachman
CEO and Chairman, Director
Jun 18, 2025Buy+2,178$2.30$5.01K1,138,437
Gabriel S. Morris
CFO, Director
Jun 18, 2025Buy+2,225$2.28$5.07K288,059
Jason Hsu
Director
Dec 23, 2024Buy+40,000$2.19$87.60K893,000
Jason Hsu
Director
Dec 20, 2024Buy+7,700$2.17$16.71K853,000
Jason Hsu
Director
Aug 22, 2024Buy+8,100$2.25$18.23K845,300
Jason Hsu
Director
Aug 21, 2024Buy+15,000$2.23$33.45K837,200
Carey Ng
Director
Aug 16, 2024Buy+10,000$1.86$18.60K20,000
Jason Hsu
Director
Jul 24, 2024Buy+6,000$2.15$12.90K822,200
Jason Hsu
Director
Jul 18, 2024Buy+3,200$2.07$6.62K816,200
Ilya M. Rachman
CEO and Chairman, Director
Jun 7, 2024Buy+2,600$2.13$5.54K1,136,259
Gabriel S. Morris
CFO, Director
Jun 7, 2024Buy+2,500$2.12$5.30K285,834
Gabriel S. Morris
CFO, Director
Jun 4, 2024Buy+3,300$1.81$5.97K283,334
Ilya M. Rachman
CEO and Chairman, Director
Jun 4, 2024Buy+3,300$1.81$5.97K1,133,659
Gabriel S. Morris
CFO, Director
May 20, 2024Award+24,141––270,844
Gabriel S. Morris
CFO, Director
May 20, 2024Award+194,218––280,034
Gabriel S. Morris
CFO, Director
May 20, 2024Award+24,141––24,141
Magda Marquet
Director
May 20, 2024Award+21,155––46,092
Ilya M. Rachman
CEO and Chairman, Director
May 20, 2024Award+218,359––1,130,359
Helen C. Adams
Director
May 20, 2024Award+74,241––174,754
Jane Buchan
Director
May 20, 2024Award+1,127––22,455
Magda Marquet
Director
May 15, 2024Award+25,002––25,002
Helen C. Adams
Director
May 15, 2024Award+87,740––100,740
Jane Buchan
Director
May 15, 2024Award+1,332––21,332
Gabriel S. Morris
CFO, Director
May 14, 2024Buy+4,500$2.23$10.04K85,816
Ilya M. Rachman
CEO and Chairman, Director
May 14, 2024Buy+4,300$2.25$9.68K912,000
Jason Hsu
Director
Dec 11, 2023Buy+31,000$4.67$144.77K813,000
Jason Hsu
Director
Dec 8, 2023Buy+25,000$4.88$122.00K782,000
Jason Hsu
Director
Sep 15, 2023Buy+7,000$2.49$17.43K757,000
Jason Hsu
Director
Sep 14, 2023Buy+10,000$2.58$25.80K750,000
Carey Ng
Director
Sep 14, 2023Buy+10,000$2.58$25.80K10,000
Jason Hsu
Director
Sep 12, 2023Buy+30,000$2.83$84.90K740,000
Helen C. Adams
Director
Sep 12, 2023Buy+13,000$2.96$38.48K13,000
Jason Hsu
Director
Sep 11, 2023Buy+25,000$2.89$72.25K710,000
Jason Hsu
Director
Sep 8, 2023Buy+10,000$2.53$25.30K685,000
Jane Buchan
Director
Sep 7, 2023Buy+20,000$2.46$49.20K20,000
Magda Marquet
Director
Sep 6, 2023Buy+9,000$2.47$22.23K20,000
Magda Marquet
Director
Sep 5, 2023Buy+10,000$2.47$24.70K11,000
Magda Marquet
Director
Aug 31, 2023Buy+1,000$2.01$2.01K1,000
Ilya M. Rachman
CEO and Chairman, Director
Nov 14, 2022Buy+1,000$0.95$950907,550
Ilya M. Rachman
CEO and Chairman, Director
Nov 14, 2022Buy+4,050$1.02$4.13K906,550
Ilya M. Rachman
CEO and Chairman, Director
Nov 14, 2022Buy+150$0.99$149907,700
Gabriel S. Morris
CFO, Director
Nov 14, 2022Buy+5,200$0.94$4.89K81,316
Sean Senn
–
Jul 14, 2022Sale−200$2.75$550899,800
Sean Senn
10% owner
Jul 14, 2022Sale−200$2.75$550899,800
Vladimir P. Torchilin
Scientific Co-Founder
Dec 20, 2021Buy+3,000$5.00$15.00K905,200
Carey Ng
Director
Dec 20, 2021Conversion+1,000,221$0.85$850.19K1,000,221
Carey Ng
Director
Dec 20, 2021Buy+25,000$5.00$125.00K1,025,221
Jason Hsu
Director
Dec 20, 2021Buy+50,000$5.00$250.00K50,000

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
18.96%
11M shares short
Days to cover
9.2
At 1M shares a day
Change since last report
+5.1%
From 11M shares
Short volume, 20 days
55.8%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Immix Biopharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 21,822 shares on Sep 3, 2026 over the last 90 days.

See a number that looks wrong?